1 study found for:    16257339 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Docetaxel

Indicates status has not been verified in more than two years